Resources | NITAG RESOURCE CENTER

2024 ∙ NACI

Interim guidance on the use of Imvamune® in the context of a routine immunization program

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus (RSV) disease in infants: Supplementary systematic review of economic evidence

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus (RSV) disease in infants

2024 ∙ NIAC

NIAC Herpes Zoster vaccine recommendations

2024 ∙ NACI

Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

2024 ∙ JCVI

JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination

2024 ∙ NIAC

Updated recommendations for the vaccination of adults against measles

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2024 ∙ NACI

Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19